Login:
Forgotten password Register
 
Practitioner 2009;253(1717):16

Weighing up risks and benefits of antidepressants

25 Apr 2009Pais-up subscribers

My current first choice antidepressant is citalopram (moderate efficacy, high acceptability, low suicide risk, intermediate half-life). While I might be tempted to consider switching to sertraline, I am not yet convinced that this would achieve a clinically significant benefit.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.
To subscribe contact: thepractitioner@servicehelpline.co.uk

Overseas subscription

Individual: £138
Institutional: £138
Overseas: +44 (0)1795 418 670
Subscription enquiry: thepractitioner@servicehelpline.co.uk

UK subscription

Individual: £85
Institutional: £85
UK: 0844 815 5934
Subscription enquiry: thepractitioner@servicehelpline.co.uk

Please fill in your login details below

 
 
Forgotten password